#United States #Cambridge #MetaVia #DA-1726 #EASL Congress

MetaVia's DA-1726: Shaping the Future of Obesity Treatment

MetaVia Inc., a leading clinical-stage biotechnology firm, announces a significant milestone with the acceptance of their late-breaking abstract highlighting their innovative dual agonist, DA-1726. This groundbreaking treatment is designed to target both GLP-1 and glucagon receptors, heralding a new strategy in the management of obesity.

The Significance of DA-1726

DA-1726 is not just another entry in the crowded obesity treatment landscape; it represents a novel approach to utilizing oxyntomodulin (OXM) analogs in clinical applications. This dual-action product is poised to impact not only weight management but also conditions associated with metabolic dysfunction, such as Metabolic Dysfunction-Associated Steatohepatitis (MASH). As reported by MetaVia's President and CEO, Hyung Heon Kim, the acceptance of the late-breaking abstract for presentation at the prestigious EASL Congress 2026 validates the strength and potential of this therapeutic asset.

Key Details of the Presentation

• - Presentation Title: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DA-1726, an Oxyntomodulin Analogue, in a Higher-Dose Phase 1 Cohort with Exploratory Noninvasive Liver Assessment
• - Presenting Author: Chris Fang, Chief Medical Officer, MetaVia
• - Abstract Number: LB26-5204
• - Session: Late Breaking Posters
• - Presentation Date: May 27, 2026, starting at 8:30 AM CET

Attendees can expect insights into the drug's safety and efficacy as DA-1726 undergoes further evaluation through a 16-week Phase 1 Part 3 titration study. This study aims to optimize dosage levels while assessing the tolerability of the treatment among participants, with comprehensive data anticipated in the fourth quarter of this year.

Clinical Potential

What makes DA-1726 particularly compelling is its mechanism of action. It not only targets GLP-1 receptors to enhance satiety but also activates glucagon receptors to boost energy expenditure effectively. Research conducted in pre-clinical studies indicates that DA-1726 outperformed conventional treatments, such as semaglutide, in promoting weight loss and managing glucose levels without sacrificing dietary intake. This distinction is crucial for patients who struggle with weight loss as it combines appetite suppression with energy elevation effectively.

Furthermore, early trials demonstrate its promising profile in preserving lean body mass while offering improved lipid-lowering properties compared to other treatments in its class.

MetaVia's Broader Vision

MetaVia is firmly committed to revolutionizing care for cardiometabolic disorders. In addition to DA-1726, the company is developing vanoglipel (DA-1241), aimed at treating metabolic dysfunction-associated steatohepatitis (MASH). This progressive research approach assures that MetaVia remains a key player in pioneering therapies that address the complex interplay between obesity and metabolic health.

The presentation at the EASL Congress not only highlights the promising research surrounding DA-1726 but also signifies a crucial moment for innovation in obesity treatment. In a world where obesity is increasingly recognized as a prime risk factor for numerous health complications, advancements like those presented by MetaVia could pave the way for enhanced therapeutic strategies and improved patient outcomes.

For more details, the full poster and presentation will be accessible on MetaVia’s website post-event. Stay tuned for updates as we delve deeper into what could become a transformative option for those battling obesity.